{"PubmedArticle": [{"MedlineCitation": {"SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "OtherAbstract": [], "CitationSubset": ["IM"], "KeywordList": [], "GeneralNote": [], "PMID": "20831681", "DateCompleted": {"Year": "2011", "Month": "02", "Day": "22"}, "DateRevised": {"Year": "2022", "Month": "04", "Day": "10"}, "Article": {"ArticleDate": [], "Language": ["eng"], "ELocationID": ["10.1111/j.1365-2710.2009.01133.x"], "Journal": {"ISSN": "1365-2710", "JournalIssue": {"Volume": "35", "Issue": "5", "PubDate": {"Year": "2010", "Month": "Oct"}}, "Title": "Journal of clinical pharmacy and therapeutics", "ISOAbbreviation": "J Clin Pharm Ther"}, "ArticleTitle": "Saffron in the treatment of patients with mild to moderate Alzheimer's disease: a 16-week, randomized and placebo-controlled trial.", "Pagination": {"StartPage": "581", "EndPage": "588", "MedlinePgn": "581-8"}, "Abstract": {"AbstractText": ["Herbal medicines have been used in the treatment of behavioural and psychological symptoms of dementia but with variable response. Crocus sativus (saffron) may inhibit the aggregation and deposition of amyloid \u03b2 in the human brain and may therefore be useful in Alzheimer's disease (AD).", "The goal of this study was to assess the efficacy of saffron in the treatment of mild to moderate AD.", "Forty-six patients with probable AD were screened for a 16-week, double-blind study of parallel groups of patients with mild to moderate AD. The psychometric measures, which included AD assessment scale-cognitive subscale (ADAS-cog), and clinical dementia rating scale-sums of boxes, were performed to monitor the global cognitive and clinical profiles of the patients. Patients were randomly assigned to receive capsule saffron 30 mg/day (15 mg twice per day) (Group A) or capsule placebo (two capsules per day) for a 16-week study.", "After 16 weeks, saffron produced a significantly better outcome on cognitive function than placebo (ADAS-cog: F=4\u00b712, d.f.=1, P=0\u00b704; CDR: F=4\u00b712, d.f.=1, P=0\u00b704). There were no significant differences in the two groups in terms of observed adverse events.", "This double-blind, placebo-controlled study suggests that at least in the short-term, saffron is both safe and effective in mild to moderate AD. Larger confirmatory randomized controlled trials are called for."], "CopyrightInformation": "Copyright \u00a9 2010 The Authors. JCPT \u00a9 2010 Blackwell Publishing Ltd."}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran Institute of Medicinal Plants (ACECR), Department of Neurology, Tehran, Iran. s.akhond@neda.net"}], "Identifier": [], "LastName": "Akhondzadeh", "ForeName": "S", "Initials": "S"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Sabet", "ForeName": "M Shafiee", "Initials": "MS"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Harirchian", "ForeName": "M H", "Initials": "MH"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Togha", "ForeName": "M", "Initials": "M"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Cheraghmakani", "ForeName": "H", "Initials": "H"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Razeghi", "ForeName": "S", "Initials": "S"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Hejazi", "ForeName": "S Sh", "Initials": "SSh"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Yousefi", "ForeName": "M H", "Initials": "MH"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Alimardani", "ForeName": "R", "Initials": "R"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Jamshidi", "ForeName": "A", "Initials": "A"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Zare", "ForeName": "F", "Initials": "F"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Moradi", "ForeName": "A", "Initials": "A"}], "PublicationTypeList": ["Journal Article", "Randomized Controlled Trial", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "J Clin Pharm Ther", "NlmUniqueID": "8704308", "ISSNLinking": "0269-4727"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Plant Preparations"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Aged"}, {"QualifierName": ["drug therapy", "physiopathology", "psychology"], "DescriptorName": "Alzheimer Disease"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cognition"}, {"QualifierName": ["adverse effects", "chemistry"], "DescriptorName": "Crocus"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": ["metabolism"], "DescriptorName": "Flowers"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Phytotherapy"}, {"QualifierName": ["adverse effects", "therapeutic use"], "DescriptorName": "Plant Preparations"}, {"QualifierName": [], "DescriptorName": "Psychiatric Status Rating Scales"}, {"QualifierName": [], "DescriptorName": "Treatment Outcome"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2010", "Month": "9", "Day": "14", "Hour": "6", "Minute": "0"}, {"Year": "2010", "Month": "9", "Day": "14", "Hour": "6", "Minute": "0"}, {"Year": "2011", "Month": "2", "Day": "23", "Hour": "6", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["20831681", "10.1111/j.1365-2710.2009.01133.x"]}}], "PubmedBookArticle": []}